Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 5/20 | 0.51 |
| ▸ | CACNA1A | O00555 | 5/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.51 |
| ▸ | CACNG3 | O60359 | 5/20 | 0.51 |
| ▸ | CACNA1F | O60840 | 5/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.51 |
| ▸ | CACNB3 | P54284 | 5/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.51 |
| ▸ | CACNG7 | P62955 | 5/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.51 |
| ▸ | CACNA1D | Q01668 | 5/20 | 0.51 |
| ▸ | CACNB1 | Q02641 | 5/20 | 0.51 |
| ▸ | CACNG1 | Q06432 | 5/20 | 0.51 |
| ▸ | CACNB2 | Q08289 | 5/20 | 0.51 |
| ▸ | CACNA1S | Q13698 | 5/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.51 |
| ▸ | CACNA1E | Q15878 | 5/20 | 0.51 |
| ▸ | CACNA2D4 | Q7Z3S7 | 5/20 | 0.51 |
| ▸ | CACNA2D3 | Q8IZS8 | 5/20 | 0.51 |
| ▸ | CACNG8 | Q8WXS5 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809256 | 0.78 | MGLL (0.68) | MEN1KMT2AMGLLALDH1A1NPC1 | |
| SCHEMBL1809539 | 0.77 | LMNA (0.51) | MEN1KMT2ACNR1ALDH1A1NPSR1 | |
| SCHEMBL1808958 | 0.77 | PROKR1 (0.61) | MEN1KMT2AMGLLALDH1A1HTT | |
| SCHEMBL29839340 | 0.77 | CACNB4 (0.45) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL22729645 | 0.77 | CACNB4 (0.45) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL1809057 | 0.76 | MGLL (0.73) | MEN1KMT2AMGLLALDH1A1LMNA | |
| SCHEMBL1808901 | 0.76 | MGLL (0.63) | MEN1KMT2AMGLLALDH1A1LMNA | |
| SCHEMBL1806591 | 0.75 | KDM4E (0.60) | MEN1KMT2AMGLLALDH1A1LMNA | |
| SCHEMBL1808791 | 0.75 | MGLL (0.53) | MEN1KMT2AMGLLALDH1A1L3MBTL1 | |
| SCHEMBL1807818 | 0.75 | MGLL (0.53) | MEN1KMT2AMGLLALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | claimed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | claimed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | claimed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | CACNB4 90/4885CACNA1A 15/4885CACNA1G 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.